[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemodialysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,103,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241",false,"NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[26,27,28,29,30,31,32,33],"Haemodialysis","Haemodialysis Complication","Vascular Access","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":20},"2026-08-01",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"Medical University of Vienna","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100626667","internal-jugular-vein-ultrasound-for-volume-status-assessment-in-haemodialysis-100626667","NCT07438613","Internal Jugular Vein Ultrasound for Volume Status Assessment in Haemodialysis","IJV-US","Inclusion Criteria:\n\n* Chronic haemodialysis\n* Informed consent\n\nExclusion Criteria:\n\n* Non ultrafiltrative treatment\n* Insufficient compliance",{"count":55,"type":20},100,"OBSERVATIONAL","To Evaluate accuracy of Internal Jugular Vein Point-of-Care ultrasound for volume status evaluation in chronic haemodialysis",[26,59,60],"Volume Assessment","Point of Care Ultrasound (POCUS)",[62,63,64],"haemodialysis","volume assessment","PoCUS","RECRUITING","2026-02-22",{"date":68,"type":38},"2026-02-27",{"date":70,"type":38},"2025-09-15",{"date":72,"type":20},"2027-09",{"name":74,"class":45},"University of Bologna",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100621967","dialysate-cooling-for-the-preservation-of-cognitive-function-in-people-receiving-haemodialysis-100621967","NCT07377500","Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis","Randomised Controlled Trial of Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis","COOL HD","Inclusion Criteria:\n\n* The participant is receiving maintenance in-centre haemodialysis\n* Over 18 years of age at time of consent\n* The participant is able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Participants with confirmed diagnosis of dementia.\n* Participants who lack capacity to consent.\n* Participants having dialysis less than three times a week.\n* Pregnant participants.",{"count":84,"type":20},356,[23],"When a person's kidneys are not working properly, they need a life-saving treatment called haemodialysis three times a week to filter the waste and extra fluids from the blood. 25 000 adults in the United Kingdom are currently having haemodialysis and unfortunately more than two-thirds of these people experience problems with thinking and memory, which may lead to dementia. These problems tend to worsen more rapidly than people who are not on haemodialysis. This decline in brain function can make it harder for people to do everyday tasks, increase their reliance on others, and lower their overall quality of life. It also raises the chances of needing hospital care and can shorten their lifespan.\n\nOne reason for this decline in thinking and memory could be the dialysis treatment itself. Research has shown that blood flow to the brain can drop during dialysis. If this happens regularly, it can harm the brain over time. Earlier studies found that cooling the dialysis fluid slightly (to 0.5°C below body temperature) helped people tolerate dialysis better and showed less brain damage on magnetic imaging brain scans (MRI) after a year, compared to those who had haemodialysis without cooling the dialysis fluid. However, the investigators still don't know if this brain protection translates into better thinking and memory for people on haemodialysis.\n\nThis study will see if cooling the dialysis fluid helps preserve thinking and memory function.\n\nThe investigators will invite participants at three hospitals with haemodialysis centres to take part. Those who agree will be randomly assigned to either standard dialysis or cooled dialysis. The investigators will assess participants' thinking and memory functions using special tests at the start of the study and again after a year. By comparing the results from both groups, the investigators hope to see if the cooled dialysis really helps protect brain.",[26,88],"Kidney Failure",[90,91,92,93],"DIALYSATE COOLING","KIDNEY FAILURE","HAEMODIALYSIS","COGNITIVE IMPAIRMENT","2026-01-30",{"date":96,"type":38},"2026-02-03",{"date":98,"type":20},"2026-04-01",{"date":100,"type":20},"2028-01-01",{"name":102,"class":45},"University Hospitals of Derby and Burton NHS Foundation Trust",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100533417","phase-2-lumasiran-in-hyperoxalaemic-patients-on-haemodialysis-100533417","NCT06225544","Lumasiran in Hyperoxalaemic Patients on Haemodialysis","LHOxH","Inclusion Criteria:\n\n* Male or female patients\n* Aged between 18 and 80 years old at the start of the study.\n* Women of child-bearing potential to consent to either abstinence or the use of contraception during the study period\n* Patients must have capacity to give written, informed consent to participate in the study prior to commencing the study. They must be fully aware of the aims, nature, planned interventions and potential risks of participating in the study. This consent must be obtained by the time of participant inclusion.\n* Established and stable on haemodialysis for at least 2 months\n* Thrice weekly haemodialysis\n* In possession of permanent dialysis access - either arterio-venous fistula (AVF) or graft (AVG) or permanent dialysis catheter\u002Ftunnelled haemodialysis line (THL).\n* ESKD not caused by previously diagnosed primary hyperoxaluria.\n* Mean baseline serum oxalate level of ≥20 μmol\u002FL\n* No recent (within last 2 months) significant changes to regular medications or diet\n\nExclusion Criteria:\n\n* Known diagnosis of PH1, 2 or 3; or a pathological mutation documented to cause primary hyperoxaluria.\n* Established on haemodialysis for less than 2 months.\n* On peritoneal dialysis.\n* Combined haemodialysis and peritoneal dialysis.\n* Temporary or poorly functioning haemodialysis access\n* Pregnancy, planning pregnancy or currently breast feeding.\n* Co-morbidity of an enteric disorder such as Inflammatory Bowel Disease (IBD), short gut syndrome, or a malabsorptive disorder.\n* Decompensated Liver failure.\n* Intercurrent active infection and\u002For antibiotic treatment.\n* Currently on Vitamin C treatment with a daily dose of more than 250mg.\n* Terminal illness and\u002For life expectancy of less than 1 year.\n* Currently relapsed or uncontrolled and symptomatic psychiatric disorder preventing compliance with the study.\n* Participants institutionalised by court or government order.\n* Patients who could be coerced due to dependency on the sponsor, the investigator, the trial sites or test centres.\n* Deranged liver function tests: If alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than twice the upper limit","80 Years",{"count":19,"type":20},[113],"PHASE2","This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis.\n\nThe study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study.\n\nAt the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.",[26,116,117,118,119],"Chronic Kidney Disease Requiring Chronic Dialysis","Cardiovascular Disease","Cardiovascular Risk Factor","Hyperoxalemia","2024-08-19",{"date":122,"type":38},"2024-08-21",{"date":124,"type":38},"2024-04-14",{"date":126,"type":20},"2025-03-01",{"name":128,"class":45},"Charite University, Berlin, Germany",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100524709","early-phase-1-comparison-between-haparin-and-herodin-in-hd-100524709","NCT06112262","Comparison Between Haparin and Herodin in HD","Comparison of the Effecta and Drawbacks of Heparin Versus Hirudin Drugs in Haemodialysis Patients in Assiut University Hospitals","Inclusion Criteria:\n\n1. patient age between 18:70\n2. Haemodialysis duration less than 6 months\n3. Agree to participate in the study\n\nExclusion Criteria:\n\n1. AKI\n2. patients with impaired coagulation profile\n3. Decompensated liver disease","70 Years",{"count":138,"type":20},98,[140],"EARLY_PHASE1","The goal of this study is to compare the efficacy and drawbacks of Heparin and Hirudin in Haemodialysis patients. The main question it aims to answer is:\n\nwhich drug is more safe in Haemodialysis?",[26],"2023-11-19",{"date":145,"type":38},"2023-11-21",{"date":147,"type":20},"2023-12-20",{"date":149,"type":20},"2026-09",{"name":151,"class":45},"Basma Rabiey"]